Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.

Autor: Helmy SA; Department of Clinical and Hospital Pharmacy, Faculty of Pharmacy, Taibah University, AL-Madinah AL-Munawarah, Saudi Arabia.; Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt., El-Morsi RM; Department of Microbiology and Immunology, Faculty of Pharmacy, Delta University for Science and Technology, Egypt., Helmy SAM; Department of Languages and Translation, College of Arts and Humanities, Taibah University, AL-Madinah AL-Munawarah, Saudi Arabia.; Department of Foreign Languages, Faculty of Education, Tanta University, Tanta, Egypt., El-Masry SM; Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Jazyk: angličtina
Zdroj: Journal of drug delivery science and technology [J Drug Deliv Sci Technol] 2022 Oct; Vol. 76, pp. 103762. Date of Electronic Publication: 2022 Sep 08.
DOI: 10.1016/j.jddst.2022.103762
Abstrakt: Vaccination is the most effective tool available for fighting the spread of COVID-19. Recently, emerging variants of SARS-CoV-2 have led to growing concerns about increased transmissibility and decreased vaccine effectiveness. Currently, many vaccines are approved for emergency use and more are under development. This review highlights the ongoing advances in the design and development of different nano-based vaccine platforms. The challenges, limitations, and ethical consideration imposed by these nanocarriers are also discussed. Further, the effectiveness of the leading vaccine candidates against all SARS-CoV-2 variants of concern are highlighted. The review also focuses on the possibility of using an alternative non-invasive routes of vaccine administration using micro and nanotechnologies to enhance vaccination compliance and coverage.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sally A. Helmy reports was provided by Damanhour University Faculty of Pharmacy. Sally A. Helmy reports a relationship with Damanhour University, Taibah University that includes: employment. Sally A. Helmy has patent pending to I don't know. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: